loading...| Preferred Name |
Abarelix |
|
| Synonyms |
|
|
| Definitions |
A synthetic decapeptide and antagonist of naturally occurring gonadotropin-releasing hormone (GnRH). Abarelix directly and competitively binds to and blocks the gonadotropin releasing hormone receptor in the anterior pituitary gland, thereby inhibiting the secretion and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone. As a result, this may relieve symptoms associated with prostate hypertrophy or prostate cancer, since testosterone is required to sustain prostate growth. |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C2015 |
|
| Accepted_Therapeutic_Use_For |
Prostate Cancer |
|
| ALT_DEFINITION |
A drug used to reduce the amount of testosterone made in patients with advanced symptomatic prostate cancer for which no other treatment options are available. It belongs to the family of drugs called gonadotropin-releasing hormone (GnRH) antagonists. |
|
| CAS_Registry |
183552-38-7 |
|
| CHEBI_ID |
CHEBI:337298 |
|
| Chemical_Formula |
C72H95ClN14O14 |
|
| code |
C2015 |
|
| Contributing_Source |
CTRP FDA |
|
| definition |
A synthetic decapeptide and antagonist of naturally occurring gonadotropin-releasing hormone (GnRH). Abarelix directly and competitively binds to and blocks the gonadotropin releasing hormone receptor in the anterior pituitary gland, thereby inhibiting the secretion and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone. As a result, this may relieve symptoms associated with prostate hypertrophy or prostate cancer, since testosterone is required to sustain prostate growth. |
|
| Display_Name |
Abarelix |
|
| FDA_UNII_Code |
W486SJ5824 |
|
| Has_Target | ||
| in_subset |
http://purl.obolibrary.org/obo/NCIT_C63923 http://purl.obolibrary.org/obo/NCIT_C177537 http://purl.obolibrary.org/obo/NCIT_C176424 http://purl.obolibrary.org/obo/NCIT_C116977 http://purl.obolibrary.org/obo/NCIT_C116978 http://purl.obolibrary.org/obo/NCIT_C128784 |
|
| Is_Value_For_GDC_Property | ||
| label |
Abarelix |
|
| Legacy Concept Name |
Abarelix |
|
| Maps_To |
Abarelix |
|
| NCI_Drug_Dictionary_ID |
415570 |
|
| PDQ_Closed_Trial_Search_ID |
415570 |
|
| PDQ_Open_Trial_Search_ID |
415570 |
|
| Preferred_Name |
Abarelix |
|
| prefixIRI |
NCIT:C2015 |
|
| prefLabel |
Abarelix |
|
| Semantic_Type |
Amino Acid, Peptide, or Protein Pharmacologic Substance |
|
| UMLS_CUI |
C1174732 |
|
| subClassOf |